14 citations
,
February 2018 in “Psychoneuroendocrinology” Mice lacking steroid 5α-reductase 2 show less aggression and better impulse control.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
3 citations
,
July 2022 in “Brain and Behavior” The HtrA1L364P mutation causes brain dysfunction and blood vessel damage.
5 citations
,
January 2018 in “Interdisciplinary sciences: computational life sciences” Accurate protein modeling can help develop new treatments for prostate cancer and other diseases.
28 citations
,
March 2013 in “Journal of Investigative Dermatology” Kv1.3 blockers may help treat alopecia areata and promote hair regrowth.
13 citations
,
August 2007 in “Bioorganic & medicinal chemistry letters” A new compound effectively inhibits human 5α-reductase 1.
22 citations
,
November 2011 in “Journal of Analytical Toxicology” Scientists have developed a new method to detect steroid abuse in athletes using cell-based tests, which could be the future of anti-doping methods.
17 citations
,
August 2011 in “Current Medicinal Chemistry” New treatments for enlarged prostate are being developed, some of which may be more effective than current medications.
402 citations
,
August 2011 in “Cancer research” Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.
April 2026 in “Therapeutic Advances in Drug Safety” Finasteride is high-risk for cognitive disorders, while Carbidopa/Levodopa, Topiramate, and Clonazepam are moderate-risk.
April 2016 in “The FASEB Journal” Blocking androgen receptors early in life increases estrogen levels and reduces sexual motivation in male rats.
July 2025 in “Journal of Investigative Dermatology” 4 citations
,
August 2023 in “Biomedicine & Pharmacotherapy” Ivacaftor can protect against noise-induced hearing loss by reducing oxidative stress.
January 2018 in “Surgical and Cosmetic Dermatology” Finasteride and dutasteride are effective for male hair loss and enlarged prostate but may cause reversible sexual side effects.
8 citations
,
September 2013 in “Molecular carcinogenesis” Rapamycin reduces skin cell growth and tumor development by affecting cell signaling in mice.
March 2023 in “The Journal of Urology” Higher SRD5A2 expression predicts better response to finasteride in treating urinary symptoms.
52 citations
,
July 1998 in “Urology” Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.
58 citations
,
June 2000 in “The Journal of Steroid Biochemistry and Molecular Biology” Different types of androgens bind differently to two receptors, AR1 and AR2, in Atlantic croaker's brain and ovarian tissues, suggesting these receptors may control different androgen actions in fish.
July 2017 in “Nursing2023” Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.
January 2020 in “Nihon Yakuri Gakkai nenkai yoshishu” Reducing 5α-reductase activity helps endometrial cells differentiate, aiding pregnancy.
September 2025 in “Journal of the American Academy of Dermatology” Using 5α-reductase inhibitors for hair loss in women doesn't increase cancer risk.
45 citations
,
August 2010 in “Hormone Molecular Biology and Clinical Investigation” Type 3 5α-reductase is more common and finasteride and dutasteride strongly inhibit it.
18 citations
,
April 2001 in “Bioorganic & Medicinal Chemistry Letters” The nature of the side chain in RU 58841 derivatives greatly affects its AR affinity, with the N-(iodopropenyl) derivative 13 showing the highest AR binding affinity, suggesting its potential for developing high-affinity radioiodinated AR radioligands.
54 citations
,
May 2015 in “Endocrinology” Manipulating 5α-reductase type 2 can affect liver fat production and glucocorticoid effects.
March 2016 in “The Journal of Urology” The discovery of 5α-reductase deficiency in guevedoces led to the development of important urologic medications.
March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
13 citations
,
September 2017 in “Life sciences” Androgens may influence bladder cancer progression by affecting cellular behavior.
March 2024 in “Cleveland Clinic journal of medicine” Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.
January 2022 in “Social Science Research Network” Potassium channel modulators mostly increase the activity of rat whisker mechanoreceptors.
August 2025 in “ACS Omega” New compounds show promise as nonsteroidal treatments for hair loss.